Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Parkinson׳s disease: Current and future pharmacotherapy
Ashish Kumar Kakkar, Neha Dahiya
European Journal of Pharmacology (2015) Vol. 750, pp. 74-81
Closed Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Development, wiring and function of dopamine neuron subtypes
Oxana Garritsen, Eljo Y. van Battum, Laurens M. Grossouw, et al.
Nature reviews. Neuroscience (2023) Vol. 24, Iss. 3, pp. 134-152
Closed Access | Times Cited: 70
Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides
Dóra Reglődi, Justine Renaud, Andrea Tamás, et al.
Progress in Neurobiology (2015) Vol. 155, pp. 120-148
Open Access | Times Cited: 153
Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools
Juliana Silva, Victoria Monge‐Fuentes, Flávia Gomes, et al.
Toxins (2015) Vol. 7, Iss. 8, pp. 3179-3209
Open Access | Times Cited: 101
Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management
K. S. Siddiqi, Azamal Husen, Sayed Sartaj Sohrab, et al.
Nanoscale Research Letters (2018) Vol. 13, Iss. 1
Open Access | Times Cited: 92
A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 2, pp. 673-688
Closed Access | Times Cited: 28
Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro
Lea Pogačnik, Katja Pirc, Inês Palmela, et al.
Brain Research (2016) Vol. 1651, pp. 17-26
Closed Access | Times Cited: 69
Elucidating the Neuroprotective Role of PPARs in Parkinson’s Disease: A Neoteric and Prospective Target
Tapan Behl, Piyush Madaan, Aayush Sehgal, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 10161-10161
Open Access | Times Cited: 46
Crystal structures, binding interactions, and ADME evaluation of brain penetrant N -substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors
Nikolay Tzvetkov, Hans‐Georg Stammler, Beate Neumann, et al.
European Journal of Medicinal Chemistry (2017) Vol. 127, pp. 470-492
Closed Access | Times Cited: 61
Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials
Brandon Conklin, Brian Conley, Yannan Hou, et al.
Advanced Drug Delivery Reviews (2022) Vol. 192, pp. 114636-114636
Open Access | Times Cited: 27
Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease
Etheresia Pretorius, Martin Pagé, Sthembile Mbotwe, et al.
PLoS ONE (2018) Vol. 13, Iss. 3, pp. e0192121-e0192121
Open Access | Times Cited: 44
In Vivo Morphology of the Optic Nerve and Retina in Patients With Parkinson's Disease
Anastasia Pilat, Rebecca J. McLean, Frank A. Proudlock, et al.
Investigative Ophthalmology & Visual Science (2016) Vol. 57, Iss. 10, pp. 4420-4420
Open Access | Times Cited: 41
Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study
Oren S. Cohen, Amihai Rigbi, Gilad Yahalom, et al.
Journal of Clinical Neurophysiology (2018) Vol. 35, Iss. 2, pp. 159-165
Closed Access | Times Cited: 40
An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases
Lea Pogačnik, Ajda Ota, Nataša Poklar Ulrih
Cells (2020) Vol. 9, Iss. 3, pp. 576-576
Open Access | Times Cited: 33
Development of internal thresholds of toxicological concern (iTTC) for chemicals based on empirical exposures to pharmaceuticals
Takaharu Takeshita, Yuko Nukada, Shota Nakagawa, et al.
Regulatory Toxicology and Pharmacology (2025), pp. 105832-105832
Closed Access
Effects of Postnatal Enriched Environment in a Model of Parkinson’s Disease in Adult Rats
Adél Jüngling, Dóra Reglődi, Zsofia Karadi, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 2, pp. 406-406
Open Access | Times Cited: 37
Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway
Rekha Raghunathan, Nicole K. Polinski, Joshua Klein, et al.
Molecular & Cellular Proteomics (2018) Vol. 17, Iss. 9, pp. 1778-1787
Open Access | Times Cited: 36
Effect of temperature, pH, β- and HP-β-cds on the solubility and stability of flavanones: Naringenin and hesperetin
Carmen Lucas-Abellán, Maravillas Pérez-Abril, Juan P. Castillo, et al.
LWT (2019) Vol. 108, pp. 233-239
Open Access | Times Cited: 31
Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson’s Disease
Tapan Behl, Piyush Madaan, Aayush Sehgal, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 678-678
Open Access | Times Cited: 16
iPiDA-SWGCN: Identification of piRNA-disease associations based on Supplementarily Weighted Graph Convolutional Network
Jialu Hou, Hang Wei, Bin Liu
PLoS Computational Biology (2023) Vol. 19, Iss. 6, pp. e1011242-e1011242
Open Access | Times Cited: 9
Diagnosis and Treatment of Neurological and Ischemic Disorders Employing Carbon Nanotube Technology
Patrick P. Komane, Yahya E. Choonara, Lisa C. du Toit, et al.
Journal of Nanomaterials (2016) Vol. 2016, pp. 1-19
Open Access | Times Cited: 31
Bee venom for the treatment of Parkinson’s disease: How far is it possible?
Kamal Awad, Abdelrahman Ibrahim Abushouk, Ahmed Abdelkarim, et al.
Biomedicine & Pharmacotherapy (2017) Vol. 91, pp. 295-302
Closed Access | Times Cited: 29
Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease
Chien‐Tai Hong, Lung Chan, Dean Wu, et al.
Parkinsonism & Related Disorders (2019) Vol. 65, pp. 224-229
Closed Access | Times Cited: 28
Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors
Hongguang Ma, Boshi Huang, Yan Zhang
Drug Discovery Today (2020) Vol. 25, Iss. 9, pp. 1682-1692
Open Access | Times Cited: 27
Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson’s disease
Atul Kabra, Uttam Singh Baghel, Christophe Hano, et al.
Journal of Ayurveda and Integrative Medicine (2020) Vol. 11, Iss. 4, pp. 448-454
Open Access | Times Cited: 25
The neuroprotective effects of isoquercitrin purified from apple pomace by high-speed countercurrent chromatography in the MPTP acute mouse model of Parkinson's disease
Cong Liu, Wenjuan Wang, Hao Li, et al.
Food & Function (2021) Vol. 12, Iss. 13, pp. 6091-6101
Closed Access | Times Cited: 22
Page 1 - Next Page

Scroll to top